Mon, November 21, 2022
Fri, November 18, 2022
Thu, November 17, 2022
Wed, November 16, 2022
Tue, November 15, 2022

Matthew Barcus Maintained (VINC) at Strong Buy with Decreased Target to $3 on, Nov 17th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-3-on-nov-17th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Barcus of Chardan Capital, Maintained "Vincerx Pharma, Inc." (VINC) at Strong Buy with Decreased Target from $4 to $3 on, Nov 17th, 2022.

Matthew has made no other calls on VINC in the last 4 months.



There is 1 other peer that has a rating on VINC. Out of the 1 peers that are also analyzing VINC, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Jonathan Chang of "SVB Leerink" Maintained at Buy with Decreased Target to $5 on, Friday, August 12th, 2022

Publication Contributing Sources